TY  - JOUR
A1  - Seif, Michelle
A1  - Einsele, Hermann
A1  - Löffler, Jürgen
T1  - CAR T cells beyond cancer: hope for immunomodulatory therapy of infectious diseases
JF  - Frontiers in Immunology
N2  - Infectious diseases are still a significant cause of morbidity and mortality worldwide. Despite the progress in drug development, the occurrence of microbial resistance is still a significant concern. Alternative therapeutic strategies are required for non-responding or relapsing patients. Chimeric antigen receptor (CAR) T cells has revolutionized cancer immunotherapy, providing a potential therapeutic option for patients who are unresponsive to standard treatments. Recently two CAR T cell therapies, Yescarta® (Kite Pharma/Gilead) and Kymriah® (Novartis) were approved by the FDA for the treatments of certain types of non-Hodgkin lymphoma and B-cell precursor acute lymphoblastic leukemia, respectively. The success of adoptive CAR T cell therapy for cancer has inspired researchers to develop CARs for the treatment of infectious diseases. Here, we review the main achievements in CAR T cell therapy targeting viral infections, including Human Immunodeficiency Virus, Hepatitis C Virus, Hepatitis B Virus, Human Cytomegalovirus, and opportunistic fungal infections such as invasive aspergillosis.
KW  - infectious diseases
KW  - mAb engineering
KW  - CAR T cells
KW  - HIV
KW  - HCV
KW  - CMV
KW  - invasive aspergillosis
KW  - HBV
Y1  - 2019
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-195596
SN  - 1664-3224
VL  - 10
IS  - 2711
ER  -